Overview

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Status:
Terminated
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Facet Biotech
Collaborator:
PDL BioPharma, Inc.
Treatments:
Visilizumab